Literature DB >> 22868806

Monocyte chemoattractant protein-1 and paraoxonase-1 and 3 levels in patients with sepsis treated in an intensive care unit: a preliminary report.

Teresa Sans1, Anna Rull, Jose Luna, Bharti Mackness, Michael Mackness, Jorge Joven, Marcos Ibañez, Rainer Pariente, Marta Rodriguez, Xavier Ortin, Gaspar Masdeu, Jordi Camps.   

Abstract

BACKGROUND: There is considerable interest in the research of molecules modulating the acute inflammatory response in patients with sepsis. Paraoxonases (PON) are antioxidant and anti-inflammatory enzymes that inhibit the production of the monocyte chemoattractant protein-1 (MCP-1). This preliminary study investigated changes in PON status and MCP-1 concentrations in critically ill patients with severe sepsis treated in an ICU and their relationship with the evolution of disease.
METHODS: This was a longitudinal, prospective and observational study on 15 patients with sepsis, studied at baseline and on days 1, 2, 5, 7 and 10 of their stay in the ICU. In all the patients we measured serum PON1 and PON3 concentrations, PON1 paraoxonase and lactonase activities, serum MCP-1 concentrations, and several standard biochemical and haematological parameters.
RESULTS: MCP-1 concentration significantly decreased with the resolution of sepsis, and this decrease was especially important during the first 5 days of hospitalisation. PON1 and PON3 tended to decrease during the first 5 days in ICU and significantly increased in days 7 and 10. Linear regression analysis showed significant and direct correlations among serum MCP-1 concentration and lactate levels at baseline. At the end of stay, PON1 paraoxonase and lactonase activities were significantly correlated with organ system function measurements.
CONCLUSIONS: We observed an inverse pattern between changes in MCP-1, and PON1 and PON3 levels in patients with sepsis, this was related to the resolution of their infection after receiving treatment in an ICU.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22868806     DOI: 10.1515/cclm-2011-0896

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  5 in total

1.  Preliminary study on serum paraoxonase-1 status and chemokine (C-C motif) ligand 2 in hospitalized elderly patients with catheter-associated asymptomatic bacteriuria.

Authors:  S Iftimie; A García-Heredia; I Pujol; F Ballester; I Fort-Gallifa; J M Simó; J Joven; J Camps; A Castro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-22       Impact factor: 3.267

2.  Temperature Trajectory Subphenotypes Correlate With Immune Responses in Patients With Sepsis.

Authors:  Sivasubramanium V Bhavani; Krysta S Wolfe; Cara L Hrusch; Jared A Greenberg; Paulette A Krishack; Julie Lin; Paola Lecompte-Osorio; Kyle A Carey; John P Kress; Craig M Coopersmith; Anne I Sperling; Philip A Verhoef; Matthew M Churpek; Bhakti K Patel
Journal:  Crit Care Med       Date:  2020-11       Impact factor: 9.296

Review 3.  Connection between the Altered HDL Antioxidant and Anti-Inflammatory Properties and the Risk to Develop Alzheimer's Disease: A Narrative Review.

Authors:  Francesca Zimetti; Maria Pia Adorni; Judit Marsillach; Cinzia Marchi; Alessandro Trentini; Giuseppe Valacchi; Carlo Cervellati
Journal:  Oxid Med Cell Longev       Date:  2021-01-08       Impact factor: 6.543

4.  Low paraoxonase 1 activity predicts mortality in surgical patients with sepsis.

Authors:  Suzana Bojic; Jelena Kotur-Stevuljevic; Nevena Kalezic; Zorana Jelic-Ivanovic; Aleksandra Stefanovic; Ivan Palibrk; Lidija Memon; Zdravko Kalaba; Marina Stojanovic; Sanja Simic-Ogrizovic
Journal:  Dis Markers       Date:  2014-02-09       Impact factor: 3.434

5.  Serial measurements of Paraoxonase-1 (PON-1) activity in horses with experimentally induced endotoxemia.

Authors:  Donatella Scavone; Micaela Sgorbini; Alexandre S Borges; José P Oliveira-Filho; Valentina Vitale; Saverio Paltrinieri
Journal:  BMC Vet Res       Date:  2020-11-04       Impact factor: 2.741

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.